The components of inventory, net as of June 30, 2022 and December 31, 2021 are as follows:

During the three-month and six-month periods ended June 30, 2021, we allocated approximately $1,000 and $5,000, respectively, of finished goods inventory for use in clinical trials. These transactions were recorded in research and development expense in the condensed consolidated statements of operations. No inventory was allocated for use in clinical trials during the three-month and six-month periods ended June 30, 2022.